Dr. Bangsberg et al., Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population, AIDS, 14(4), 2000, pp. 357-366
Objective: To examine the relationship between adherence, viral suppression
and antiretroviral resistance in HIV-infected homeless and marginally hous
ed people on protease inhibitor (PI) therapy.
Design and setting: A cross-sectional analysis of subjects in an observatio
nal prospective cohort systematically sampled from free meal lines, homeles
s shelters and low-income, single-room occupancy (SRO) hotels.
Participants: Thirty-four HIV-infected people with a median of 12 months of
PI therapy.
Main outcomes: Adherence measured by periodic unannounced pill counts, elec
tronic medication monitoring, and self-report; HIV RNA viral load; and HIV-
1 genotypic changes associated with drug resistance.
Results: Median adherence was 89, 73, and 67% by self-report, pill count, a
nd electronic medication monitor, respectively. Thirty-eight per cent of th
e population had over 90% adherence by pill count. Depending on the measure
, adherence explained 36-65% of the variation in concurrent HIV RNA levels.
The three adherence measures were closely related. Of 20 genotyped patient
s who received a new reverse transcriptase inhibitor (RTI) when starting a
Pi, three had primary protease gene substitutions. Of 12 genotyped patients
who received a PI without a new RTI, six had primary protease gene substit
utions (P < 0.03).
Conclusion: A substantial proportion of homeless and marginally housed indi
viduals had good adherence to PI therapy. A strong relationship was found b
etween independent methods of measuring adherence and concurrent viral supp
ression. PI resistance was more closely related to the failure to change RT
I when starting a PI than to the level of adherence. (C) 2000 Lippincott Wi
lliams & Wilkins.